The EU Commission clears a merger subject to remedies on the market of medical devices (Bard / BD)

Mergers: Commission approves acquisition of Bard by BD, subject to conditions* The European Commission has approved, under the EU Merger Regulation, the acquisition of Bard by BD. Both companies supply medical devices. The decision is conditional on the divestment of BD's core needle biopsy devices business, and tissue marker product that is currently under development. C. R. Bard, Inc. ("Bard") and Becton, Dickinson and Company ("BD") are both US companies active globally in the supply of medical devices, including devices used in biopsies. Commissioner Margrethe Vestager, in charge of competition policy, said: "The conditions we have imposed on this merger will help to ensure that millions of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission clears a merger subject to remedies on the market of medical devices (Bard / BD), 18 October 2017, e-Competitions Bulletin November 2017, Art. N° 85040

Visites 45

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues